Stocks › IONS
Ionis Pharmaceuticals Inc (IONS) stock analysis
SKIP 11% confidence · analysed Nov 3, 2026
On Nov 3, 2026, our model rated Ionis Pharmaceuticals Inc (IONS) SKIP with 11% confidence at a price of $40.42. That means the signals cancel out; the model sees no clear edge either way.
Technical picture
The 14-day RSI is 42. Momentum is soft: below the neutral 50 line, but not yet oversold.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price is below both its 50-day and 200-day moving averages, the classic picture of a downtrend.
Volume is about normal (1.4x the 20-day average).
Trend structure and money flow
Market structure shows a bearish break of structure (BOS): price broke a recent swing low in the direction of the trend, which usually signals trend continuation.
The most recent swing high is $86.74 and the swing low is $68.90; traders often treat these as resistance and support.
Fundamentals
The PEG ratio is 27.33, which looks expensive relative to its growth.
The company reports a profit margin of -64.7% and revenue growth of -40.7%.
In its latest quarter it earned $-0.42 per share, which beat the $-0.88 analysts expected, with revenue -40.7% year over year.
Wall Street's average rating is 1.7 on a 1 (strong buy) to 5 (sell) scale, roughly a "buy", with an average price target of $84.13.
The next earnings report is expected around Nov 9, 2026; prices often move sharply around earnings.
The model's one-paragraph read
No clear edge (SKIP) — composite score -0.11 (SKIP). Technicals: RSI 41.85, MACD bullish, price below SMA50. Fundamentals: PEG 27.33, margin -64.7%, revenue growth -40.7%. Financial results: YoY revenue -40.7%, last EPS surprise +52.3%, next earnings 2026-11-09. Smart Money Concepts: BOS bearish (trend continuation), equal highs above (resting liquidity). FinGPT news read: positive. Reference price $40.42; no trade levels (SKIP).
Past ratings for IONS
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Nov 3, 2026 | SKIP | 11% | $40.42 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on IONS
- Nov 3, 2026: Ionis Faces First Real Test Of Tringolza's Broad SHTG Launch As Shares Sit Near Lows (Earnings Whispers)
Frequently asked questions
Is IONS a buy right now?
As of Nov 3, 2026, our automated model rates Ionis Pharmaceuticals Inc (IONS) SKIP with 11% confidence: the signals cancel out; the model sees no clear edge either way. This is a model output for education, not personal investment advice.
When does Ionis Pharmaceuticals Inc report earnings next?
The next earnings report is expected around Nov 9, 2026.
What does a SKIP rating mean?
A SKIP rating means the signals cancel out; the model sees no clear edge either way.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.